29
November 2024
Aptamer Group
plc
("Aptamer", the "Company" or the "Group")
Annual General Meeting
Statement
Aptamer Group plc (AIM: APTA), the
developer of novel Optimer® binders to enable innovation
in the life sciences industry, will hold its Annual General Meeting
(AGM) at 10:00 am today at the offices of Aptamer Group, Windmill
House, Innovation Way, York, YO10 5BR.
Dr
Adam Hargreaves, Non-Executive Chairman will provide the following
statement:
"I am delighted with the progress
made by Aptamer Group. Since the fundraising of £2.6m in July this
year, we have met our cost-base reduction targets, streamlined our
scientific production capabilities, and executed our new commercial
growth strategy to deliver optimised products of high quality to
our growing customer base.
Attracting new partners has ensured
that we are now working with the majority of the larger global
pharmaceutical companies, alongside a wealth of diagnostic,
healthcare, and niche biotech partners. Particular highlights have
included the development of a vertical market platform in fibrosis,
in which we are working with AstraZeneca; the progression toward
human trials of our deodorant Optimer product with Unilever; and
the successful production of an Optimer delivery conjugate to an
undisclosed genetic medicines company, with which they are planning
pre-clinical trials.
Our increased commercial traction
has secured newly signed contracts, currently up to the value of
£471,000, which will ensure that the Group's cash runway remains
generous, allowing any licensing opportunities to evolve and
potentially crystalise over this extended period.
The Board looks forward to updating
shareholders on further progress in due course."
The AGM will provide no new material
information. Results of the AGM will be announced to the London
Stock Exchange and placed on the Group's website, in the usual way,
as soon as practicable after the conclusion of the AGM.
- Ends -
For
further information, please contact:
|
Aptamer Group plc
Arron Tolley, Chief Executive
Officer
|
+44 (0) 1904 217
404
|
|
SPARK Advisory Partners Limited - Nominated
Adviser
Andrew Emmott / Adam
Dawes
|
+44 (0) 20 3368
3550
|
|
Turner Pope Investments (TPI) Limited -
Broker
James Pope / Andrew
Thacker
|
+44 (0) 20 3657
0050
|
|
NorthStar Communications Limited - Investor
Relations
Sarah Hollins
|
+44 (0) 113 730 3896
|
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary
Optimer® platform to enable new approaches in
therapeutics, diagnostics, and research applications. The Company
strives to deliver transformational solutions that meet the needs
of life science researchers and
developers. Optimer binders are
oligonucleotide affinity ligands that can function as an antibody
alternative. The global affinity ligand market is currently worth
over $170 billion.
Aptamer has successfully delivered
projects for a range of global pharma companies, diagnostic
development companies, and research institutes, covering multiple
application areas with the objective of establishing
royalty-bearing licenses.
To register for news alerts by email
go to https://aptamergroup.com/investors/investor-news-email-alerts/.